Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Pembrolizumab
75%
Non Small Cell Lung Cancer
70%
Programmed Death 1 Ligand 1
66%
Epidermal Growth Factor Receptor
46%
Neoplasm
37%
Placebo
33%
Small Cell Lung Cancer
33%
Trilaciclib
33%
Cancer of Unknown Primary Origin
33%
Positron Emission Tomography
33%
Lung Adenocarcinoma
33%
Phase II Trials
33%
Atezolizumab
33%
Albumin
33%
Abdominal Cancer
33%
Tumor
33%
Tumor Mutational Burden
33%
Glucose
33%
Progression Free Survival
19%
Overall Survival
19%
Monotherapy
16%
Etoposide
14%
Exclusion Criterion
12%
Glycogen Synthase Kinase
12%
Adverse Event
10%
Intention-to-Treat Analysis
10%
Prospective Study
8%
Serum Albumin
8%
Doctor of Philosophy
8%
Alprenolol
8%
Mortality Rate
8%
Diagnosis
8%
Hematopoietic Cell
7%
Carboplatin
7%
Pemetrexed
6%
Hazard Ratio
6%
Median Follow Up
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy Regimens
100%
Trilaciclib
66%
Small Cell Lung Cancer
66%
Placebo
54%
Pembrolizumab
33%
Trastuzumab
33%
Metastatic Breast Cancer
33%
Neoplasm
33%
Non Small Cell Lung Cancer
33%
Programmed Death 1 Ligand 1
33%
Vinorelbine
33%
Afatinib
33%
Phase II Trials
33%
Atezolizumab
33%
Etoposide
18%
Neutropenia
14%
Overall Survival
10%
Epidermal Growth Factor Receptor
8%
Febrile Neutropenia
8%
Bone Marrow Suppression
7%
Monotherapy
7%
Carboplatin
7%
Pemetrexed
6%
Adverse Event
5%
